Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
9.66
-2.06 (-17.55%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Neurogene Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-75.14-36.32-55.19-50.52
Depreciation & Amortization
3.253.33.20.95
Asset Writedown & Restructuring Costs
0.09---
Loss (Gain) From Sale of Investments
-2.42-0.11--
Stock-Based Compensation
8.321.421.250.9
Other Operating Activities
1.26-15.690.610.68
Change in Accounts Payable
-0.080.67-3.612.98
Change in Other Net Operating Assets
-5.88-4.690.91-1.39
Operating Cash Flow
-70.6-51.42-52.82-46.4
Capital Expenditures
-0.81-0.32-2.23-18.37
Cash Acquisitions
-20.96--
Investment in Securities
-124.455--
Investing Cash Flow
-125.2625.64-2.23-18.37
Long-Term Debt Repaid
-0.05-0.03-0-
Net Debt Issued (Repaid)
-0.05-0.03-0-
Issuance of Common Stock
1.680.170.070.29
Other Financing Activities
182.4592.34--
Financing Cash Flow
184.0792.4866.5351.06
Net Cash Flow
-11.7966.711.48-13.71
Free Cash Flow
-71.41-51.74-55.05-64.77
Free Cash Flow Margin
-7720.11%---
Free Cash Flow Per Share
-4.07-11.11-139.54-15.99
Cash Interest Paid
0.010.010-
Levered Free Cash Flow
-49.42-16.42-36.68-
Unlevered Free Cash Flow
-49.41-16.42-36.68-
Change in Net Working Capital
8.54-13.933.58-
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q